Skip to main navigation Skip to search Skip to main content

Effectiveness and safety of non-vitamin-K antagonist oral anticoagulants versus warfarin in atrial fibrillation patients with thrombocytopenia

  • Chun Li Wang
  • , Victor Chien Chia Wu
  • , Cheng Hung Lee
  • , Chang Fu Kuo
  • , Yu Ling Chen
  • , Pao Hsien Chu
  • , Shao Wei Chen
  • , Ming Shien Wen
  • , Lai Chu See
  • , Shang Hung Chang*
  • *Corresponding author for this work
  • Chang Gung Memorial Hospital
  • Chang Gung University
  • Chang Gung University of Science and Technology

Research output: Contribution to journal › Journal Article › peer-review

33 Scopus citations

Abstract

Patients with thrombocytopenia were excluded from major clinical trials that investigated non-vitamin-K antagonist oral anticoagulants (NOACs) for stroke prevention in atrial fibrillation (AF). The aim of this study was to evaluate the effectiveness and safety of NOAC versus warfarin in AF patients with thrombocytopenia. From 2010 to 2017, a cohort study based on electronic medical records of a multi-center healthcare provider in Taiwan and included 8239 anticoagulated AF patients (age 77.0 ± 7.3 years, 48.0% female). Patients were divided into two subgroups: 7872 patients with a normal platelet count and 367 patients (4.4%) with thrombocytopenia, which was defined as a platelet count less than 100 × 10 3 /µL. We performed Cox proportional hazard analyses to compare the risks of ischemic stroke or systemic embolism (IS/SE), major bleeding, and death between NOAC and warfarin therapies in patients with a normal platelet count and those with thrombocytopenia, respectively. In patients with a normal platelet count, NOAC therapy (n = 4904) was associated with a significantly lower risk of major bleeding, with no difference in the risk of IS/SE or death when compared with warfarin therapy (n = 2968). In patients with thrombocytopenia, NOAC therapy (n = 181) was associated with a lower tendency for major bleeding (aHR 0.45, 95% CI 0.16–1.14) with no significant difference in IS/SE (aHR 0.94, 95% CI 0.29–2.91) or death (aHR 0.95, 95% CI 0.46–1.95) when compared with warfarin therapy (n = 186). NOAC therapy is a reasonable choice for stroke prevention in AF patients with thrombocytopenia.

Original languageEnglish
Pages (from-to)512-519
Number of pages8
JournalJournal of Thrombosis and Thrombolysis
Volume47
Issue number4
DOIs
StatePublished - 15 05 2019

Bibliographical note

Publisher Copyright:
© 2018, Springer Science+Business Media, LLC, part of Springer Nature.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Atrial fibrillation
  • Bleeding
  • Oral anticoagulation
  • Stroke
  • Thrombocytopenia
  • Warfarin

Fingerprint

Dive into the research topics of 'Effectiveness and safety of non-vitamin-K antagonist oral anticoagulants versus warfarin in atrial fibrillation patients with thrombocytopenia'. Together they form a unique fingerprint.

Cite this